📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. (2013)

First Author: Talapatra SK

Attributed to: Alignment of Synthesis, Medicinal Chemistry and Structural Genomics to Accelerate UK Drug Discovery: Network SMS-Drug funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/jm4006274

PubMed Identifier: 23875972

Publication URI: http://europepmc.org/abstract/MED/23875972

Type: Journal Article/Review

Volume: 56

Parent Publication: Journal of medicinal chemistry

Issue: 16

ISSN: 0022-2623